Dicumarol: Difference between revisions
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
Line 25: | Line 25: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
Revision as of 16:47, 4 September 2012
Clinical data | |
---|---|
ATC code | |
Pharmacokinetic data | |
Protein binding | plasmatic proteins |
Metabolism | hepatic |
Excretion | faeces, urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C19H12O6 |
Molar mass | 336.295 g/mol |
WikiDoc Resources for Dicumarol |
Articles |
---|
Most recent articles on Dicumarol |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Dicumarol at Clinical Trials.gov Clinical Trials on Dicumarol at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Dicumarol
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Dicumarol Discussion groups on Dicumarol Directions to Hospitals Treating Dicumarol Risk calculators and risk factors for Dicumarol
|
Healthcare Provider Resources |
Causes & Risk Factors for Dicumarol |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information, click here
Dicumarol (or Dicoumarol) is an anticoagulant that functions by as a Vitamin K antagonist (similar to warfarin).
It is a derivative of coumarin.
External links
- Template:DiseasesDB
- Cullen J, Hinkhouse M, Grady M, Gaut A, Liu J, Zhang Y, Weydert C, Domann F, Oberley L (2003). "Dicumarol inhibition of NADPH: quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism". Cancer Res. 63 (17): 5513–20. PMID 14500388.
- Mironov A, Colanzi A, Polishchuk R, Beznoussenko G, Mironov A, Fusella A, Di Tullio G, Silletta M, Corda D, De Matteis M, Luini A (2004). "Dicumarol, an inhibitor of ADP-ribosylation of CtBP3/BARS, fragments golgi non-compact tubular zones and inhibits intra-golgi transport". Eur J Cell Biol. 83 (6): 263–79. PMID 15511084.
- Abdelmohsen K, Stuhlmann D, Daubrawa F, Klotz L (2005). "Dicumarol is a potent reversible inhibitor of gap junctional intercellular communication". Arch Biochem Biophys. 434 (2): 241–7. PMID 15639223.
- Thanos C, Liu Z, Reineke J, Edwards E, Mathiowitz E (2003). "Improving relative bioavailability of dicumarol by reducing particle size and adding the adhesive poly(fumaric-co-sebacic) anhydride". Pharm Res. 20 (7): 1093–100. PMID 12880296.
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- CS1 maint: Multiple names: authors list
- Drug
- Cardiology